News | July 20, 2009

ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe for Ablation


July 20, 2009 - ATS Medical Inc. today announced the first commercial use of the new ATS CryoMaze 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.

The cryoablation procedure was performed by Niv Ad, M.D., chief of cardiac surgery at the Inova Heart and Vascular Institute in Falls Church, Virginia. The ATS CryoMaze 10-S Probe is a linear cryoablation probe that is more rigid than the current ATS CryoMaze probes. The increased support throughout the length of the 10-S probe addresses the preference of some surgeons to have more probe leverage to achieve contact with targeted tissue that is difficult to reach, the company said. In addition, the increased stiffness of the ATS CryoMaze 10-S Probe will optimize the shape retention of the malleable probe, which is particularly useful in minimally invasive procedures.

The new cryoablation probe leverages the second generation, argon-based ATS CryoMaze System that quickly achieves the coldest probe temperatures available for cardiac arrhythmia surgery, the company said. The argon-based cryoablation system routinely reaches probe temperatures of -160 degrees Celsius compared to first generation nitrous-oxide systems, which only reach temperatures of -65 degrees Celsius. The colder probe temperatures provide faster, deeper lesions yielding greater confidence that transmural, linear lesions are being achieved, especially in clinical situations in which varying tissue thickness is the rule, the company said.

The proprietary design utilized in all ATS CryoMaze Probes allows them to be easily shaped by hand without the need for a tool to control the radius of the bends. The probe tip can be repeatedly reshaped intraoperatively to meet the different anatomic requirements of the individual patient and procedure. The "bellows" design of the ATS CryoMaze Probes facilitates this durable probe malleability without kinking and/or fractures.

"The ATS CryoMaze System is very well equipped for minimally invasive stand-alone surgery for atrial fibrillation. The new, more rigid 10-S probe is a great addition that makes it easier to apply lesions and complete full biatrial Maze-III procedures," said Dr. Ad.

For more information: www.atsmedical.com


Related Content

News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
Subscribe Now